CDEK
← All drugs Report issue

rebamipide

Small moleculeexperimental

Rebamipide, an amino acid derivative of 2-(1H)-quinolinone, is used for mucosal protection, healing of gastroduodenal ulcers, and treatment of gastritis. It works by enhancing mucosal defense, scavenging free radicals, and temporarily activating genes encoding cyclooxygenase-2. — Wikipedia

Clinical trial activity

60 trials · 54 clinical orgs · 0 marketing orgs

Phase 1
12
Phase 2
33
Phase 3
20
Phase 4
11

Earliest trial started Jan 1, 2004 (NCT00233389)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1
Mol. weight
370.79 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2-(4-chlorobenzoylamino)-3-(2(1h)-quinolinon-4-yl)propionic acid
  • mucosta
  • opc 12759
  • opc-12759
  • opc-12759
  • opc-12759
  • proamipide
  • rebamidpide
  • rebamipide
  • rebamipide
  • rebamipide
  • rebamipide
  • rebamipide
  • rebamipide
  • rebamipide
  • rebamipide
  • rebamipide, (-)-isomer
  • rebamipide, (+)-isomer
  • repamipide
  • sa001
  • sa-001
  • sjp002

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06084624Phase 1/Phase 2 (Phase 2)Dec 31, 2023Cairo University
NCT07297316Phase 4Oct 3, 2022Korea University, Kukje Pharma
NCT05166304Phase 1/Phase 2 (Phase 2)Jan 31, 2022October 6 University
NCT05202405Phase 1Jan 5, 2022Addpharma Inc.
NCT05072938Phase 4Nov 30, 2021Daewoong Pharmaceutical Co. LTD.
NCT05131997Phase 3Sep 14, 2021Addpharma Inc., Yonsei University
NCT04885751Phase 4Jun 1, 2021Dong-A Pharmaceutical, Seoul National University
NCT04649697Phase 3Dec 1, 2020Cairo University
NCT05269810Phase 2May 29, 2020Samjin Pharmaceutical Co., Ltd., Yonsei University
NCT04189705Phase 3Dec 31, 2019Chung-Ang University, Otsuka
NCT04685395Phase 3Dec 26, 2019Cairo University
NCT04066530Phase 3Sep 4, 2019Addpharma Inc., Korea University
NCT04150146Phase 1Jul 5, 2019Otsuka
NCT04150172Phase 1Apr 22, 2019Otsuka
NCT03608761Phase 4Feb 6, 2018Hospital Nacional Profesor Alejandro Posadas
NCT03437785Phase 2Jan 16, 2018Chong Kun Dang Pharmaceutical
NCT03723811Phase 2Nov 28, 2017Catholic University of Korea, Samjin Pharmaceutical Co., Ltd.
NCT03723798Phase 2Nov 8, 2017Catholic University of Korea, Samjin Pharmaceutical Co., Ltd.
NCT02924155Phase 1Sep 1, 2016Samjin Pharmaceutical Co., Ltd., Seoul National University
NCT05303961Phase 1Jun 7, 2016Samjin Pharmaceutical Co., Ltd.
Showing 20 of 60 trials
Page 1 / 3

Organizations

Research & Development (54)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
OtsukaFor profit252142004
Yonsei UniversityAcademic/Hospital7152010
Samjin Pharmaceutical Co., Ltd.For profit6622015
Seoul National UniversityAcademic/Hospital5132010
Catholic University of KoreaAcademic/Hospital4032010
Korea UniversityAcademic/Hospital4132010
Acucela Inc.For profit3322009
Addpharma Inc.For profit3322019
Cairo UniversityAcademic/Hospital3322019
Dong-A PharmaceuticalFor profit3222010
Soonchunhyang UniversityAcademic/Hospital3022010
AbbottFor profit2212007
Ajou UniversityAcademic/Hospital2022010
Biolab Sanus FarmaceuticaFor profit2122014
Chonnam National UniversityAcademic/Hospital2122008
Chung-Ang UniversityAcademic/Hospital2012010
Galeno Desenvolvimento de PesquisasAcademic/Hospital2122014
Hallym UniversityAcademic/Hospital2122009
IlDong Pharmaceutical Co LtdFor profit2222013
Inje UniversityAcademic/Hospital2022010
54 organizations
Page 1 / 3